Keyphrases
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Bacillus Calmette
54%
Radical Prostatectomy
40%
Robot-assisted Radical Cystectomy
39%
Open Radical Cystectomy
37%
Docetaxel
36%
Radical Cystectomy
34%
Interferon-α (IFN-α)
32%
Intracorporeal Urinary Diversion
31%
Extracorporeal Urinary Diversion
29%
Prostate Cancer
29%
Bacillus Calmette-Guérin
28%
Intravesical
28%
Obesity
27%
Intracorporeal
27%
Rényi Entropy
27%
Gemcitabine
23%
Intravesical Gemcitabine
22%
Signal Receiver
22%
Ultrasonic
22%
Treatment Failure
22%
Oncological Outcomes
21%
Salvage Therapy
19%
Recurrence-free Survival
18%
Metastasis Cancer
18%
Prostate Cancer Risk
18%
Micro-ultrasound
18%
Distant Metastasis
18%
Major Complications
18%
Robotics
18%
Molecular Imaging
18%
Entropy-based
18%
Intravesical Therapy
18%
Bladder Cancer
17%
Subtle Change
16%
Single Institution
15%
Postoperative Outcomes
14%
Radio Frequency
13%
Treatment-naïve
12%
Shannon Entropy
12%
Prostate
12%
Soft Tissue
11%
Kaplan-Meier Method
11%
Perioperative Complications
10%
Receiver-driven
10%
Adverse Pathology
10%
Chemotherapy
10%
Pathologic
10%
Active Surveillance
10%
Prostatectomy Specimen
9%
Medicine and Dentistry
Non Muscle Invasive Bladder Cancer
86%
Cystectomy
77%
Prostate Cancer
68%
Extracorporeal
45%
Prostatectomy
45%
Diseases
38%
Docetaxel
36%
Gemcitabine
36%
Urinary Diversion
35%
Interferon
23%
Intravesical Drug Administration
22%
Mycobacterium Bovis BCG
21%
Salvage Therapy
21%
Immunotherapy
21%
Bladder
20%
Bladder Cancer
19%
Kidney Tumour
18%
Distant Metastasis
18%
Malignant Neoplasm
18%
Recurrence Free Survival
17%
Neoplasm
16%
Body Mass Index
15%
Recurrent Disease
13%
Kaplan Meier Method
13%
Biopsy Technique
12%
Proportional Hazards Model
12%
Stricture
11%
Magnetic Resonance Imaging
11%
Gleason Score
10%
Clear Cell Renal Cell Carcinoma
10%
Drug Therapy
9%
Rescue Therapy
9%
Germinoma
9%
Non Muscle Invasive Treatment of Bladder Cancer
9%
Prostatitis
9%
Cytotoxic T-Cell
9%
Kidney Cancer
9%
Cancer Mortality
9%
Kidney Stone
9%
Cohort Analysis
9%
Urodynamics
9%
Candiduria
9%
Testes
9%
Neurogenic Bladder
9%
Cancer Growth
9%
Urinary Tract Infection
9%
Interferon Alfa 2b
9%
Pelvis
9%
Cancer Risk
9%
Germ Cell
9%